Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
FIGURE 1.
Images of patient 1. (A) After initial brachytherapy, no tumor detection within prostate is achievable with CT alone. (C) With ¹⁸F-PSMA-1007 PET/CT, good delineation of local recurrence is possible. (B) Maximum-intensity projection highlights advantage of low urinary clearance, because no PET signal derives from urinary bladder. Arrows indicate location of tumor.
Download figure
Open in new tab
Download powerpoint
FIGURE 2.
Images of patient 8, who presented with BCR after radical prostatectomy and salvage radiotherapy. ¹⁸F-PSMA-1007 PET/CT (maximum-intensity projection, A) detected recurrent disease with multiple bone metastases (B and C) and LN metastases (D–G) 8 y after initial diagnosis. All images were acquired 3 h after injection. Arrowheads indicate locations of tumors.
Download figure
Open in new tab
Download powerpoint
FIGURE 3.
(A) Tumor SUV_max increased from 1 to 3 h after injection in all lesion groups. (B) Ratios of SUV_max to blood pool presented improved contrast at delayed time point. Data are mean and SE.
Download figure
Open in new tab
Download powerpoint
FIGURE 4.
(A) Analysis of short-axis diameter of ¹⁸F-PSMA-1007–positive LNs indicates that ¹⁸F-PSMA-1007 PET/CT detects micrometastases that could be missed on CT or MRI. (B) No dependency of SUV_max on lesion diameter was found. Orange dashed reference lines are shown for short-axis diameter of 8 mm and SUV_max of 2.0.

TABLE 1

Patient Characteristics